

## Safety assessment of food additives Impact of the changes in EFSA scientific methodology for deriving a reference point

### BACKGROUND

The **no observed adverse effect level (NOAEL)** is the greatest concentration or amount of a substance at which no detectable adverse effects occur in an exposed population.

**The NOAEL has been used historically as the reference point (RP) for estimating the health-based guidance values (HBGVs) such as acceptable daily intakes (ADIs) for food additives** in long-term animal in vivo studies. To derive an ADI a safety or uncertainty factor (commonly 100) is applied to the NOAEL in the most sensitive test species. The 100-fold safety factor is considered to be the product of both species and inter-individual differences in toxicokinetics and toxicodynamics.

**The Benchmark Dose (BMD)** is the minimum dose of a substance that produces a clear, low level health risk, usually in the range of a 1-10% change in a specific toxic effect such as cancer induction. The lower bound (BMDL) is needed as a potential RP, and the upper bound (BMDU) is needed for establishing the BMDU/BMDL per ratio reflecting the uncertainty in the BMD estimate.

In 2022, EFSA's Scientific Committee updated its [guidance on the use of the benchmark dose \(BMD\) approach in EFSA's risk assessments as an alternative to the traditional No-Observed-Adverse-Effect-Level \(NOAEL\) approach](#)<sup>1</sup>.

**EFSA has reconfirmed its recommendation to use the BMD approach instead of the traditionally used NOAEL approach to identify a Reference Point**, since it makes a more extended use of dose–response data and allows for a quantification of the uncertainties in the dose–response data. EFSA considers that the BMD approach is a scientifically more advanced method compared to the NOAEL approach for deriving a RP.

In principle, the BMD approach is applicable to all chemicals for which a dose–response relationship exists for at least one endpoint, irrespective of their category (e.g. pesticide, **food additive**, contaminant) **or origin (chemically synthesised or from natural sources)**.

---

<sup>1</sup> EFSA 2009 guidance was already updated in 2017. The update in 2022 introduces among others Bayesian model averaging as well as a harmonised set of dose-response models for continuous and quantal responses. Applications and user manuals (BMD & Bayesian BMD) are available on the [EFSA R4EU Platform](#).